Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Halcinonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.72 |
| ▸ | PGR | P06401 | 7/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.72 |
| ▸ | AR | P10275 | 3/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.60 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Halcinonide SCHEMBL28149502 | 0.99 | NR3C1 (0.71) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL8571550 | 0.95 | NR3C1 (0.65) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL10802060 | 0.95 | NR3C1 (0.71) | NR3C1PGRCYP3A4ARUSP2 | |
| Fluocinolone Acetonide SCHEMBL8451856 | 0.91 | NR3C1 (0.60) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL28138594 | 0.87 | NR3C1 (0.55) | NR3C1PGRCYP3A4ARUSP2 | |
| Fludrocortisone SCHEMBL1333577 | 0.86 | NR3C1 (0.80) | NR3C1PGRCYP3A4ARHIF1A | |
| Desonide SCHEMBL8649633 | 0.85 | NR3C1 (0.69) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL24015431 | 0.85 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL8467031 | 0.85 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 | |
| Halcinonide SCHEMBL7861670 | 0.85 | NR3C1 (1.00) | NR3C1PGRCYP3A4ARUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174064-A1 | COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST AND GLUCOSE ANHYDROUS | Arven IIac Sanayi Ve Ticaret A.S. (TR) | 2015-06-25 | — | — | US | claimed |
| CN-106278999-B | S1P regulator | 比奥根MA公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-106278999-A | S1p regulator | 比奥根MA公司 | 2017-01-04 | — | — | CN | disclosed |
| CN-103533835-B | S1P modulators | 比奥根MA公司 | 2016-08-24 | — | — | CN | disclosed |
| EP-0896541-A4 | — | — | 1999-03-24 | — | — | EP | disclosed |
| EP-0896541-A1 | SILVER-BASED PHARMACEUTICAL COMPOSITIONS | CAPELLI, Christopher C. (US) | 1999-02-17 | — | — | EP | disclosed |
| WO-1997002038-A1 | SILVER-BASED PHARMACEUTICAL COMPOSITIONS | CAPELLI CHRISTOPHER C (US) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174064-A1 | COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST AND GLUCOSE ANHYDROUS | CHRM3, CHRM2, CHRM5 | NR3C1 379/4885PGR 1798/4885CYP3A4 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.